Boston Scientific Corp. vs. Haemonetics Corporation
Boston Scientific Corp. (BSX) comes out ahead, leading on 9 of 9 compared factors.
Size & Scale
| BSX | HAE | |
|---|---|---|
| Market Cap | $65.19 billion | $4.68 billion |
| Revenue (TTM) | $21.00 billion | $1.35 billion |
| Net Income (TTM) | $3.67 billion | $96.29 million |
BSX leads on 3 of 3 size & scale factors.
Valuation
| BSX | HAE | |
|---|---|---|
| P/E Ratio | 18.21 | 49.68 |
| Price / Book | 2.59 | 5.59 |
| Price / Sales | 3.10 | 3.46 |
BSX leads on 3 of 3 valuation factors.
Profitability
| BSX | HAE | |
|---|---|---|
| Net Margin | 17.47% | 7.12% |
| Return on Equity | 14.58% | 11.50% |
BSX leads on 2 of 2 profitability factors.
Risk & Sentiment
| BSX | HAE | |
|---|---|---|
| Short Interest | 0.72% | 1.81% |
BSX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, HAE overview, HAE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.